Pacific Edge (Pacific Edge) Momentum Rank : 0 (As of Jun. 21, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pacific Edge Momentum Rank?

Pacific Edge has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pacific Edge Momentum Rank Related Terms

Thank you for viewing the detailed overview of Pacific Edge's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Edge (Pacific Edge) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (OTCPK:PFGTF) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

PEB:New Zealand PEB:Australia

Address

87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016

Website

https://www.pacificedgedx.com

Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.